Using stem cells and mini-organs to model diseases and develop personalized treatments

Patient-derived tumor organoids (PDTOs), established directly from primary tumors or metastases, retain the intratumoral heterogeneity, mutational signatures, and histoarchitecture of the parental tissue. These models have been successfully generated from a wide spectrum of malignancies, including colorectal, gastric, pancreatic, ovarian, breast, lung, bladder, and glioblastoma [12]. For instance, colorectal cancer PDTOs have demonstrated predictive value for chemoradiation response. Pancreatic cancer PDTOs derived from patients treated with FOLFIRINOX have been used to model adaptive resistance involving reactive oxygen species (ROS), DNA damage, and stem-like transcriptional states [13].

In ovarian cancer, PDTOs allow functional stratification based on homologous recombination deficiency, facilitating response prediction to PARP inhibitors [14]. In glioblastoma, PDTOs co-cultured with autologous CAR-T cells enable the evaluation of antigen-specific immune responses in an immunocompetent context [15]. Additionally, tumor–stroma co-cultures using matched fibroblasts and immune cells have been shown to recapitulate tumor-immune crosstalk, including modulation of checkpoint ligand expression and cytokine secretion profiles, highlighting their use in evaluating immunotherapeutic efficacy and resistance mechanisms.

Beyond drug response prediction, PDTOs have been instrumental in large-scale therapeutic screening. For example, MTAP deficiency has been identified as a druggable vulnerability in pancreatic cancer [16]; SIRT1 overexpression in bladder cancer PDTOs has been linked to poor prognosis and resistance [17]; and HER2 amplification has guided HER2-targeted therapy in gastric and breast cancer organoids [18]. Co-culture models integrating cancer-associated fibroblasts, autologous immune cells, and endothelial cells further enhance the physiological relevance of PDTOs, enabling studies of immune evasion, stromal remodeling, and anti-angiogenic strategies. Importantly, PDTOs are increasingly being used in early-phase clinical trials to guide personalized treatment strategies and functional validation of molecular diagnostics [19].

In addition, recent applications of organoid systems include modeling responses to novel non-invasive modalities such as Tumor-Treating Fields (TTFs), which use alternating electric fields to inhibit tumor cell division in glioblastoma [20]. Notably, PDTO platforms also serve as validation systems for CRISPR-engineered tumoroids carrying defined oncogenic combinations (e.g., APC/KRAS/TP53/SMAD4), thereby linking genome-engineered hypotheses to clinically anchored functional outputs [21].

Collectively, these studies exemplify how organoid-based cancer models advance both mechanistic understanding and precision-therapy development. Their ability to integrate tumor genetics, microenvironmental interactions, and functional drug responses positions PDTOs as a central decision-support system in translational oncology.

iPSC-derived neural organoids provide access to human neurodevelopment and neurodegeneration in patient-specific contexts. In Alzheimer’s disease (AD), cortical organoids harboring PSEN1 or APP mutations recapitulate amyloid-β plaque accumulation and tau hyperphosphorylation, enabling the study of γ-secretase inhibitors [22]. Midbrain organoids derived from patients with SNCA triplication exhibit dopaminergic neuron loss and mitochondrial dysfunction, closely resembling Parkinson’s disease pathology, and serve as platforms for LRRK2 kinase inhibitor screening [23]. These organoids also exhibit impaired mitochondrial biogenesis and synaptic dysfunction, mirroring the early pathophysiological features of PD.

Motor neurons differentiated from iPSCs of patients with ALS carrying SOD1 mutations show hallmark features, such as cytoplasmic TDP-43 mislocalization and axonal transport defects, facilitating phenotypic drug screening [24]. Neurons derived from C9ORF72 repeat-expansion patients demonstrate RNA foci and toxic dipeptide repeat proteins, supporting therapeutic screening with antisense oligonucleotides.

Beyond disease modeling, neural organoids increasingly support precision-medicine applications by enabling patient-specific profiling of pathway-targeted therapies. Compared with 2D neuronal cultures, neural organoids capture multicellular interactions and network-level dysfunction more effectively, thereby enhancing the predictive value of therapeutic assessments in neurodegenerative disease models.

iPSC-derived organoids have significantly contributed to our understanding of both monogenic and complex diseases. In cystic fibrosis, intestinal organoids homozygous for the CFTR F508del mutation exhibit defective chloride transport, which can be quantified using forskolin-induced swelling assays. CRISPR/Cas9-mediated gene correction of CFTR restores normal function and validates therapeutic efficacy ex vivo [25].

Retinal organoids generated from patients with RPGR mutations replicate photoreceptor degeneration characteristic of retinitis pigmentosa [26]. Pancreatic islet-like organoids derived from iPSCs have been integrated into microfluidic “pancreas-on-a-chip” systems to evaluate β-cell function and insulin secretion in cystic fibrosis–related diabetes [27].

iPSC-derived hepatocyte-like cells from patients with PNPLA3 I148M mutations—associated with non-alcoholic fatty liver disease (NAFLD)—display lipid accumulation and endoplasmic reticulum (ER) stress upon fatty acid exposure [28]. Additionally, cortical neurons derived from patients with schizophrenia exhibit reduced dendritic spine density and aberrant synaptic pruning in response to inflammatory cytokines, implicating neuroimmune dysregulation in disease progression [29].

In several of these models, CRISPR-based allele correction or pathway perturbation has begun to clarify genotype-driven mechanisms—for example, restoration of RPGR or PNPLA3 variants—which provides direct evidence linking genetic causality with functional reversibility [28]. A consolidated overview of representative disease models derived from iPSC and organoid systems is provided in Table 2, summarizing key genetic perturbations, phenotypic outputs, and applications across neurological, metabolic, and oncologic conditions.

Collectively, these examples highlight the versatility of patient-derived stem-cell and organoid systems for modeling diverse disease mechanisms and for establishing preclinical foundations for precision medicine. By capturing the cascade from genomic variation to multicellular dysfunction within controlled isogenic contexts, these systems establish a functional bridge between molecular perturbations and clinically actionable phenotypes.

CRISPR knock-out and knock-in approaches have enabled researchers to dissect gene functions in a variety of disease contexts. These classic modalities remain the foundation of functional genomics and are most powerful when combined with iPSC- and organoid-based systems that preserve patient-specific genomic backgrounds.

By integrating KO/KI editing with organoid differentiation workflows, investigators can reconstruct disease progression from the earliest mutational events to tissue-level dysfunction, providing mechanistic insight that directly informs therapeutic strategy.

In cancer biology, CRISPR knock-in of oncogenic mutations such as APC, TP53, KRAS, SMAD4, and PIK3CA into intestinal organoids reconstructs the stepwise transformation from normal epithelium to colorectal adenocarcinoma, enabling the study of mutation-specific tumorigenesis and drug responses [21]. Similarly, in pancreatic organoids, sequential insertion of KRAS, TP53, CDKN2A, and SMAD4 mutations recapitulates the progression from pancreatic intraepithelial neoplasia (PanIN) to pancreatic ductal adenocarcinoma (PDAC) [31]. In liver cancer models, knock-out of BAP1 in human liver organoids demonstrates tumor suppressor function, with loss of epithelial polarity and enhanced proliferation typical of hepatocellular carcinoma (HCC) phenotypes [32]. Additionally, TP53/PTEN double knock-out in murine liver organoids induces intrahepatic cholangiocarcinoma (ICC)-like transformation, recapitulating the histopathological features of aggressive biliary tract cancers [33].

Beyond oncology, similar CRISPR-based approaches have been extended to non-cancer contexts, allowing mechanistic dissection of neurological and metabolic diseases that were previously inaccessible in vivo. In neurodegenerative disease research, CRISPR-based gene editing has enabled the functional dissection of congenital enzyme deficiencies and mitochondrial pathophysiology using patient-specific organoids. A representative study by Lieberman et al. employed NGLY1-deficient patient-derived iPSCs to generate midbrain organoids and established isogenic CRISPR-corrected controls to investigate disease-relevant phenotypes. The NGLY1-deficient organoids exhibited reduced neuroepithelial expansion, a loss of FOXA2 + progenitors, and delayed dopaminergic differentiation. Multi-omic analyses further revealed compromised oxidative phosphorylation and mitochondrial dysfunction. Notably, CRISPR-mediated correction of the NGLY1 mutation restored neurodevelopmental and metabolic features, validating the causal role of NGLY1 loss-of-function mutations and illustrating the utility of gene-edited isogenic organoids in modeling rare neurodevelopmental disorders [34].

Similarly, in Alzheimer’s disease (AD), CRISPR-mediated knock-out of ABCA7 in human iPSC-derived cortical neurons uncovered a previously uncharacterized mechanism involving disrupted mitochondrial lipid metabolism. ABCA7-deficient neurons showed impaired mitochondrial morphology, increased reactive oxygen species, and dysregulated cholesterol esterification. These abnormalities were rescued by CRISPR-corrected isogenic controls, implicating ABCA7 in maintaining lipid homeostasis and mitochondrial function in neuronal cells [35]. In autism spectrum disorder (ASD), CHD8 haploinsufficiency has been modeled in human cerebral organoids using CRISPR-mediated gene knock-out, recapitulating key features of ASD such as abnormal neural progenitor proliferation, disrupted cortical layer formation, and altered expression of early neurodevelopmental markers (e.g., TBR1, FOXP1). Single-cell RNA-sequencing revealed dysregulation of synaptic signaling pathways and upregulation of Wnt and Notch signaling, suggesting CHD8’s critical role in neurogenesis and cortical circuit formation [36]. These studies collectively demonstrate that KO/KI approaches not only recapitulate disease phenotypes but also enable causal assignment of molecular dysfunction within a controlled isogenic background, which is essential for mechanistic interpretation and target validation.

Beyond neurological disorders, CRISPR modeling has been applied to vascular, dermatological, renal, and metabolic conditions. In vascular malformations, knock-in of the TIE2^L914F^ gain-of-function mutation in iPSC-derived endothelial cells induces constitutive PI3K/AKT signaling, abnormal vessel pruning, and ectatic vascular structures, recapitulating key clinical features of venous malformation [37]. In dermatology, CRISPR knock-out of GALNT family genes in skin organoids has demonstrated the essential role of mucin-type O-glycosylation in epithelial stratification, basal keratinocyte proliferation, and epidermal barrier integrity [38].

In cystic fibrosis, intestinal organoids harboring CFTR F508del mutations display defective cAMP-dependent chloride secretion. The forskolin-induced swelling (FIS) assay enables ex vivo functional screening of CFTR modulators, supporting personalized therapeutic approaches. In liver disease, iPSC-derived hepatocyte-like cells carrying the PNPLA3 I148M variant exhibit lipid accumulation, oxidative stress, and impaired mitochondrial metabolism, mirroring NAFLD pathology.

The deletion of nephrogenic genes in human pluripotent stem cell–derived kidney organoids has enabled the modeling of congenital anomalies of the kidney and urinary tract, facilitating the study of nephron development and genetic malformations [39]. Moreover, CRISPR knock-out in iPSC-derived cardiomyocytes identified human-specific transporters SLCO1A2 and SLCO1B3 that mediate doxorubicin uptake and toxicity, suggesting actionable targets for precision cardioprotection [40]. Finally, CRISPR knock-out in iPSC-derived macrophages uncovered regulators of innate immune pathways, including TLR signaling and autophagy [41].

Taken together, KO/KI studies establish a blueprint for causal inference within isogenic human tissues, enabling reconstruction of multi-hit oncogenic trajectories, validation of rare-disease variants, and scalable mechanistic annotation across organ systems. However, KO/KI approaches are limited when dosage sensitivity, essential-gene function, or fine-grained transcriptional tuning is required—scenarios where base editing or CRISPRa/i is more appropriate.

CRISPRa and CRISPRi extend the functionality of CRISPR by modulating gene expression without altering the underlying DNA sequence [42]. These transcriptional modulation systems serve as precision tools that complement genome-editing approaches by enabling dynamic, reversible regulation of gene networks in iPSC- and organoid-based disease models. Unlike nuclease-dependent CRISPR editing, CRISPRa/i operates on an epigenetic and transcriptional level, offering a safer and less disruptive alternative for targeting dosage-sensitive or essential genes, an advantage particularly emphasized in organoid systems where genomic instability must be minimized.

CRISPRa uses a catalytically inactive Cas9 (dCas9) fused to transcriptional activators, such as VP64 or p300, to enhance gene expression [43]. Unlike knock-in strategies that permanently modify target loci, CRISPRa activates endogenous promoters without altering DNA, thereby preserving chromatin architecture and minimizing clonal variability. This technique has been employed to investigate the HNF4A gene regulatory network in human kidney organoids, providing insights into proximal tubule differentiation and function [44]. Additionally, CRISPRa has been utilized in human iPSC-derived microglia to uncover regulators of disease states and identify key transcriptional networks involved in neurodegenerative disorders such as AD [45]. By enabling tunable gene activation, CRISPRa facilitates the systematic interrogation of developmental and stress-response pathways, bridging mechanistic gene discovery with therapeutic target validation. Recent studies also demonstrate the utility of CRISPRa in multiplex activation screens using pooled sgRNA libraries, enabling parallel upregulation of dozens to hundreds of candidate genes to map lineage-specifying or disease-modifying pathways in organoid systems.

In contrast, CRISPRi utilizes dCas9 fused to transcriptional repressors, such as KRAB, to silence target genes [46]. Functionally, CRISPRi represents the inhibitory counterpart of CRISPRa, allowing stable yet reversible transcriptional repression without introducing double-strand breaks. In iPSC-derived astrocytes, CRISPRi has been employed to identify and elucidate regulators of distinct inflammatory reactive states, providing insights into neuroinflammatory pathways [47]. Additionally, in glioma research, CRISPRi-based screens have been used to identify lncRNA targets that modulate radiation responses in glioma cells and brain organoids, thereby uncovering potential therapeutic interventions [48]. CRISPRi’s high on-target specificity and low mutational footprint make it particularly suitable for essential-gene interrogation, synthetic lethality mapping, and buffering-network analysis within complex 3D tissues.

Together, CRISPRa and CRISPRi form a bidirectional transcriptional control axis: CRISPRa provides gain-of-function, CRISPRi loss-of-function. Both systems can be multiplexed, exhibit low mutational footprints, and maintain stable perturbation profiles within 3D tissues.

In contrast to irreversible KO/KI editing, CRISPRa/i offers fine-grained, tunable, and reversible perturbations—ideal for investigating gene-dosage effects, transient disease states, network buffering, and complex combinatorial pathway logic.

Thus, the CRISPRa/i layer adds regulatory resolution that KO/KI alone cannot achieve, completing the functional-modulation spectrum required for a comprehensive precision-medicine toolkit.

High-throughput CRISPR screening enables systematic and quantitative identification of disease-driving genes, pathway dependencies, and synthetic-lethal interactions across iPSC- and organoid-derived models. In colorectal cancer, combinatorial knock-out of TGFBR2 and SMAD4 revealed synthetic lethality under TGF-β signaling pressure, highlighting strategies for targeting resistance in microsatellite-stable tumors [49]. These scalable perturbation platforms now permit multi-dimensional mapping of gene-function networks under defined microenvironmental or cytokine conditions, enabling functional interrogation of context-specific vulnerabilities and enhancing mechanistic resolution in disease modeling [50].

Integrating CRISPR screening with multi-omics approaches, particularly single-cell RNA sequencing (scRNA-seq), ATAC-seq, and spatial transcriptomics, enables single-cell–resolved reconstruction of perturbed regulatory hierarchies. For example, in liver organoids, the OSCAR platform profiled more than 80,000 cells across 246 CRISPR perturbations, combining transcriptomic and lineage-tracing signatures to identify Fos and Ubr5 as regulators of hepatocyte specification and metabolic zonation [51]. In melanoma, CRISPR-guided base-editing coupled with scRNA-seq delineated adaptive transcriptional reprogramming and mapped SOX10–MITF regulatory axes underlying tumor plasticity and immune evasion [52].

Such integrative approaches reveal non-linear regulatory rewiring that cannot be captured by bulk analyses and simultaneously expose several current bottlenecks, including culture-to-culture variability, editing-efficiency heterogeneity, and challenges in harmonizing multi-omic datasets across laboratories [53]. In addition, incorporating basic translational performance metrics—such as predictive concordance, assay turnaround time, and culture success rates—will further clarify the clinical utility of CRISPR-integrated organoid screens. Emerging consortium-level reporting frameworks and FAIR-like standards for perturbation datasets are expected to enhance reproducibility and support future regulatory acceptance [54, 55].

Machine-learning algorithms further expand these multi-omic datasets into predictive frameworks. Supervised and graph-based learning models improve sgRNA design by modeling sequence–efficacy relationships, integrate high-dimensional omics features into latent regulatory manifolds, and prioritize candidate biomarkers through feature attribution and network centrality analyses. In papillary renal cell carcinoma, ML-assisted CRISPR screening uncovered SERPINH1 as a prognostic determinant linked to extracellular matrix remodeling and drug response heterogeneity [56–58]. Recent work has also shown that generative modeling and hybrid mechanistic–statistical models can simulate perturbation outcomes across organoid differentiation trajectories, offering an in silico complement to experimental screens and enabling hypothesis filtering before wet-lab validation [59]. Beyond target identification, AI-driven models now support cross-laboratory normalization of CRISPR screens, probabilistic estimation of therapeutic response curves, and adaptive optimization of editing strategies [60].

To ensure reproducibility and clinical readiness, standardized computational pipelines and harmonized data schemas are essential. Containerized workflows with version-controlled reference genomes, batch-correction matrices, and cross-modal feature alignment can minimize algorithmic drift. Furthermore, emerging guidelines emphasize the need for transparent reporting of sgRNA design criteria, perturbation efficiency metrics, and multi-omic integration steps to support inter-study comparability [61]. In parallel, interoperable data-sharing frameworks and model cards that document dataset provenance, hyperparameter configuration, and performance benchmarks will be indispensable for regulatory transparency and external validation.

Collectively, the convergence of high-throughput CRISPR screening, multi-omics integration, and AI-assisted analytics provides a scalable, reproducible engine for precision-medicine discovery—linking molecular perturbations to clinically actionable phenotypes with interpretability and cross-platform robustness. This integrated workflow increasingly functions as a translational scaffold that connects mechanistic gene perturbation to clinically relevant endpoints, thereby accelerating the development of individualized therapeutic strategies across diverse disease contexts.

Genotype-guided models have been pivotal in elucidating mutation-specific mechanisms and testing targeted interventions. In cystic fibrosis, caused primarily by the F508del mutation in the CFTR gene, patient-derived intestinal organoids enable quantitative functional assays of CFTR activity and allow the testing of modulator drugs such as Ivacaftor, Lumacaftor, and Trikafta, which restore chloride-channel conductance and show strong correlation with clinical response metrics [25]. In hypertrophic cardiomyopathy (HCM), iPSC-derived cardiomyocytes carrying MYH7 mutations exhibit increased sarcomere tension and impaired ATP utilization, clarifying mutation-specific bioenergetic defects. These models have facilitated rational drug development, including the design of Mavacamten, a myosin ATPase inhibitor that reduces sarcomere contractility and normalizes myocardial output [63, 64].

In colorectal cancer, organoids engineered with APC, KRAS, TP53, and SMAD4 mutations model stepwise tumorigenesis and enable genotype-specific drug screening. Organoids harboring KRAS or APC mutations identified synthetic lethality via combined EGFR and MEK inhibition, providing a mechanistic rationale for clinical polytherapy design [65]. Similarly, gastric and pancreatic tumor organoids stratified by ERBB2 amplification or BRCA mutation exhibit differential sensitivity to HER2-targeted or PARP-inhibitor therapies [66–68].

In neurodegenerative disorders, patient-specific iPSC-derived organoids have advanced the mechanistic dissection of genotype–phenotype coupling. iPSCs carrying SNCA or LRRK2 mutations differentiate into dopaminergic neurons that display mitochondrial dysfunction and α-synuclein aggregation, providing direct assay platforms for LRRK2 kinase inhibitors [69, 70]. Alzheimer’s disease organoids harboring PSEN1 or APP mutations reproduce amyloid-β deposition and enable γ-secretase inhibitor testing [71–73]. In addition, integrative genomic and transcriptomic studies have elucidated key regulatory networks and molecular subtypes associated with disease heterogeneity, revealing distinct gene expression profiles that may serve as patient-specific therapeutic targets [74]. One such example is the identification of IDE (insulin degrading enzyme) regulatory variants that influence Alzheimer’s disease risk by modulating IDE expression in the brain, as demonstrated by integrative expression and genome-wide association analyses [75]. These findings underscore the value multi-omics–driven, genotype-informed precision strategies in identifying individualized treatment approaches for Alzheimer’s disease.

Beyond the central nervous system (CNS), RPGR-mutant retinal organoids have facilitated CRISPR-based gene correction and pharmacological screening for retinitis pigmentosa [76]. In metabolic disorders such as NAFLD, liver organoids engineered with PNPLA3 or TM6SF2 variants are used to test FXR and PPAR agonists, providing a platform for genotype-dependent lipid metabolism intervention [77, 78].

While genotype defines the molecular blueprint, phenotype-based models capture emergent disease features shaped by epigenetic, environmental, and multicellular interactions. Patient-derived organoids faithfully reproduce tissue morphology, dynamic signaling, and drug-response heterogeneity in vitro, allowing real-time profiling and functional validation of therapeutic responses.

In oncology, organoids derived from pancreatic and gastric tumors display subtype-specific phenotypes, such as basal-like versus classical morphology in pancreatic cancer, which correlate with the response to FOLFIRINOX or gemcitabine [79, 80]. Ovarian cancer organoids classified by homologous recombination deficiency (HRD) predict response to PARP inhibitors such as Olaparib with > 80% ex vivo–to–clinical concordance, demonstrating the predictive validity of phenotype-driven platforms [81].

In infectious diseases, brain organoids have revealed ZIKA virus–induced phenotypes, such as cortical thinning and progenitor cell apoptosis. These models enabled the repurposing of Sofosbuvir to inhibit viral replication in human neural progenitor cells [82, 83]. Cardiomyocytes derived from iPSCs of patients with long QT syndrome or dilated cardiomyopathy display distinct electrophysiological signatures—delayed repolarization and reduced contractile amplitude—that serve as quantitative phenotypic readouts for β-blocker or ion-channel modulator testing [84–86].

Integrating genotype- and phenotype-based modeling provides a mechanistic framework for linking molecular perturbations to emergent biological function. Rather than viewing genotype and phenotype as isolated endpoints, this integration treats them as interdependent layers within a dynamic regulatory hierarchy, where information flows bidirectionally between molecular networks and system-level outcomes. In patient-derived systems, this bidirectional information flow becomes experimentally tractable because genome engineering can be coupled with quantitative phenotyping across developmental, metabolic, and tissue-level readouts.

At the experimental level, organoid and iPSC-based platforms serve as intermediate translators between genomic variation and functional phenotypes. Functional reconstitution of patient-derived variants has revealed that pathogenic mutations often reshape developmental and metabolic pathways via non-linear feedback within signaling networks rather than through simple loss or gain of function [87]. In β-catenin-related neurodevelopmental disorders, for example, reconstituted mutations within iPSC-derived organoids demonstrate graded alterations in Wnt-responsive transcriptional programs and neuronal patterning consistent with patient-specific phenotypic spectra. Such approaches illustrate how controlled genetic perturbation can elucidate the causal path from genomic variation to complex tissue-level outcomes and enable more refined stratification of molecular subtypes based on differential pathway engagement.

At the systems scale, emerging frameworks describe genotype-to-phenotype translation as a cascade across a hierarchy of cellular subsystems, where perturbations in gene regulatory circuits propagate through metabolic and signaling networks to yield coordinated phenotypic states [88]. This view emphasizes that phenotypic stability arises from network-level compensation and feedback, and that disease manifests when these buffering mechanisms are exceeded. Within this hierarchical context, organoid models provide an empirical means to quantify propagation of perturbations and identify control nodes whose modulation can restore functional homeostasis, for example, via rescue phenotyping in isogenic pairs or network-rewiring analysis in single-cell datasets.

Analytically, multi-scale data integration has become essential for capturing these cross-level interactions. Single-cell transcriptomic, chromatin-accessibility, and proteomic datasets are now merged through graph-based and probabilistic learning approaches to map latent relationships between genetic variation and phenotypic output [89]. Explainable AI frameworks further enhance interpretability by linking molecular features to emergent functional states and predictive biomarkers while also quantifying how specific genomic edits influence regulatory trajectories during organoid differentiation.

Quantitative benchmarks such as predictive concordance (70–90%), culture-success rate (70–85%), and assay turnaround time (10–21 days) are increasingly used to assess reproducibility and translational readiness in organoid-based precision-medicine pipelines [90]. Recent studies in gastrointestinal and colorectal tumor organoids have reported approximately 80% concordance between ex-vivo drug responses and clinical outcomes [91], with culture-success rates exceeding 70% under optimized media conditions [92], and streamlined drug-screening pipelines achieving turnaround times of 4–6 weeks that are clinically actionable [93]. These metrics underscore the growing maturity of organoid-based assays as translationally deployable precision-medicine tools.

Conceptually, this integration forms a translation-ready knowledge layer that underpins clinical implementation without overlapping its regulatory domain. Recent analyses of genomic-driven precision-medicine infrastructure highlight the importance of technological readiness—standardized bioinformatics pipelines, validated cellular reference models, and interoperable data frameworks—to support reproducibility and scalable deployment [94]. As these infrastructures continue to evolve, genotype–phenotype integration is expected to support prospective patient stratification, adaptive clinical-trial design, and real-time therapeutic decision-making across heterogeneous disease populations. Together, these advances transform genotype-phenotype integration from a descriptive exercise into a predictive, mechanistically grounded foundation for precision medicine.

Not applicable.

Not applicable.

The authors declare no competing interests.

All data (or sources thereof) relevant to this study are included in the article, and further inquiries can be directed to the corresponding author.